The exploration of EpCAM-targeted therapies, such as the bispecific T-cell engaging antibodies (BiTE) that show efficacy against ovarian cancer cells, underscores the potential of EpCAM as a target for innovative therapeutic interventions. The gene discussed is EPCAM; the disease is ovarian carcinoma.